Document Detail


Efficacy and safety of estriol replacement therapy for climacteric women.
MedLine Citation:
PMID:  7641124     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: As an estrogen derivative, estriol is rather effective in the relief of climacteric symptoms due to estrogen deficiency. When given one dose a day, it will not provoke endometrial proliferation and shedding. Thus, it is suitable for postmenopausal women who no longer want to have uterine bleeding and for those with comparatively higher risk of endometrial hyperplasia. In the aspect of postmenopausal osteoporosis, the prevention of further bone loss due to estrogen deficiency is also important and to be evaluated. METHODS: We collected 20 patients, aged 44-62 years, who had undergone either natural or surgical menopause and were treated with estriol succinate (Synapause; Organon; Holland 2 mg/tab) 2 mg/day for 2 years, with relief of climacteric symptoms evaluated after the first 3 months of treatment. Bone mineral density (BMD) of lumbar spine was measured using quantitative computed tomography (QCT) after one and two years of treatment, respectively. RESULTS: Estriol was very effective in the improvement of major subjective climacteric complaints in 86% of patients, especially hot flush and insomnia within 3 months. The atrophic genital changes caused by estrogen deficiency were also improved satisfactorily. No subjective symptoms induced by the therapy were seen. The rate of uterine bleeding was low, complained by only one patient. However, our study did not show the preventive effect of estriol against osteoporosis. CONCLUSIONS: Estriol can be a safe and effective alternative in the relief of climacteric symptoms for postmenopausal women, but it cannot prevent the bone loss.
Authors:
T S Yang; S H Tsan; S P Chang; H T Ng
Related Documents :
9205634 - A co-twin study of the effect of calcium supplementation on bone density during adolesc...
8440364 - Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma ...
11393574 - Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperf...
9695314 - Evaluation of the drug therapy for established osteoporosis by dual-energy x-ray absorp...
2569394 - Spread of analgesia and ventilatory response to carbon dioxide following epidural somat...
10219334 - Trends in infection morbidity in a pediatric oncology ward, 1986-1995.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Zhonghua yi xue za zhi = Chinese medical journal; Free China ed     Volume:  55     ISSN:  0578-1337     ISO Abbreviation:  Zhonghua Yi Xue Za Zhi (Taipei)     Publication Date:  1995 May 
Date Detail:
Created Date:  1995-09-21     Completed Date:  1995-09-21     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  0005327     Medline TA:  Zhonghua Yi Xue Za Zhi (Taipei)     Country:  TAIWAN    
Other Details:
Languages:  eng     Pagination:  386-91     Citation Subset:  IM    
Affiliation:
Department of Obstetrics and Gynecology, Veterans General Hospital-Taipei, Taiwan, R.O.C.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Climacteric / drug effects*
Estriol / adverse effects,  therapeutic use*
Estrogen Replacement Therapy*
Female
Humans
Middle Aged
Osteoporosis, Postmenopausal / prevention & control
Chemical
Reg. No./Substance:
50-27-1/Estriol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A clinical study of colorectal cancer accompanied by cancer of other organs.
Next Document:  Preeclampsia in multiple pregnancy.